Do Employers Cover GLP-1 Drugs? What's Happening to Coverage in 2027

Whether your job-based plan covers Wegovy, Zepbound or another GLP-1 for weight loss depends mostly on how big your employer is. In 2025, 19% of firms with 200 or more workers covered GLP-1 drugs for weight loss in their largest health plan, including 43% of firms with 5,000 or more workers — up from 28% in 2024 ^{[7] [6]}. Most employers in the Business Group on Health’s survey cover GLP-1s for diabetes, while 67% cover them for weight management ^{[3] [5]}.

Is that coverage going away? For some workers, yes. The share of large employers covering GLP-1s for weight management fell from 72% in 2025 to 60% in 2026, and 14% of employers have already eliminated weight-loss GLP-1 coverage or plan to do so in 2027 ^{[2] [30]}. Among employers still covering, 72% said they are likely to continue in 2027 and 10% said they likely will not ^{[3] [5]}. No federal law requires an employer plan to cover these drugs for weight loss or for diabetes, so the answer for any specific plan lives in the plan documents ^[6].

How many employers cover GLP-1 weight-loss drugs right now?

The most widely cited figures come from KFF’s 2025 Employer Health Benefits Survey, the 27th annual edition, which included 1,862 interviews with non-federal public and private firms and was published on October 22, 2025 ^[1]. Employer-sponsored insurance covers 154 million people under age 65 ^[1].

KFF found that 19% of firms with 200 or more workers cover GLP-1s for weight loss in their largest plan, and that coverage climbs sharply with firm size: 43% of firms with 5,000 or more workers covered them in 2025, a significant jump from 28% in 2024 ^{[7] [6]}. A Fisher Phillips review of the same KFF data rounds the 200+ figure to nearly 20% and describes the 43% figure as an almost 54% increase over the prior year ^[6].

Other surveys point in the same direction for large employers. Mercer found that 44% of companies with more than 500 employees cover the drugs for obesity ^[4]. The Business Group on Health found that 67% of its large-employer members cover GLP-1s for weight management in 2026 ^{[4] [3] [5]}.

Survey	Who is counted	Share covering weight-loss GLP-1s
KFF 2025 [7]	Firms with 200+ workers	19%
KFF 2025 [7]	Firms with 5,000+ workers	43% (up from 28% in 2024)
Mercer [4]	Companies with 500+ employees	44%
Business Group on Health [4] [3]	Large-employer members	67% in 2026

These figures apply to employers. The KFF findings are for firms with 200 or more workers ^{[1] [7]}.

Why do the KFF, Mercer and Business Group on Health numbers disagree?

The surveys count different employers. KFF samples firms with 10 or more workers and reports breakouts for firms with 200 or more, 1,000 to 4,999, and 5,000 or more workers ^{[1] [7]}. Mercer defines a large employer as one with more than 500 employees ^[4]. The Business Group on Health figures come from its membership of large employers; its GLP-1 survey was fielded between February and March 2026 among 105 members ^{[3] [5]}.

Coverage also rises with firm size in KFF’s own data — 19% among firms with 200 or more workers versus 43% among firms with 5,000 or more ^[7]. A survey drawn from very large employers will therefore report a higher share than one sampling across a wider range of firm sizes. That is why KFF’s 19% figure and the Business Group on Health’s 67% can both be accurate — they are describing different populations ^{[7] [3]}.

Is employer coverage expanding or shrinking for 2027?

The most recent signals point to coverage peaking and starting to shrink among large employers. The Business Group on Health’s 2027 Employer Healthcare Strategy Survey found the share of organizations covering GLP-1s for weight management fell from 72% in 2025 to 60% in 2026 ^{[2] [30]}. In its GLP-1 survey, among employers currently covering, 72% said they are likely to continue coverage through 2027 and 10% said they likely will not ^{[3] [5]}.

Reuters reported that about 10% of employers who now cover GLP-1 drugs for weight loss plan to drop them in 2027, citing the Business Group on Health, while a separate Mercer survey found 5% of large employers (over 500 employees) plan to drop coverage in 2027 ^[4]. The consultancy Aon also expects GLP-1 coverage to decrease next year ^[4]. Starbucks ended its coverage of GLP-1s for weight loss beginning in October 2026 ^[30].

On the other side of the ledger, few employers without coverage are adding it. KFF found that a majority of employers whose plans do not cover GLP-1s for weight loss said they are “not likely” to begin covering them within the next 12 months, and only 1% said they were “very likely” to do so ^[6]. The Business Group on Health likewise reports that companies not covering GLP-1s for weight management today are unlikely to add coverage in the future ^{[5] [3]}. KFF’s report also notes that some employers have already stopped covering these medications for weight loss, with a few even tightening coverage for people with diabetes ^[6].

Why are employers pulling back on GLP-1 coverage?

Cost is the main driver, and the pressure came faster than many employers expected. Among firms covering GLP-1s for weight loss, 59% of firms with 5,000 or more workers and 44% of firms with 1,000 to 4,999 workers say use of the medications was higher than expected ^{[7] [6]}. Sixty-four percent of large firms say GLP-1 coverage moderately or significantly impacted their prescription drug spending, including 66% of the largest employers (5,000+) who report a “significant” impact ^{[7] [6]}.

Nearly eight in 10 employers in the Business Group on Health survey call GLP-1s a major contributor to rising healthcare costs ^[3]. In a Mercer survey, 47% of respondents say GLP-1 costs over the next three years are very concerning or significantly concerning ^[3]. Mercer’s November National Survey of Employer-Sponsored Health Plans found employers expect health benefit costs to rise 6.7%, topping $18,500 per employee on average, up from $17,964 in 2025 ^[3]. Marsh’s survey projects total health benefit cost per employee will rise by 8.2% on average in 2027, the highest increase since 2003, and weight-loss drugs are the single largest contributor to that record-setting increase ^{[29] [30]}.

The potential pool of users is enormous: 34% of non-elderly people with employer-sponsored insurance — 36.2 million people — have a body mass index that would medically qualify them for a GLP-1 drug ^[7]. The Business Group on Health identifies three structural cost pressures: high commercial-market prices, significant and growing demand, and the need for long-term or lifelong use ^[2]. Employers also worry about waste when people discontinue therapy, use the medications inappropriately, or do not receive the behavioral and clinical support needed to maintain a healthy weight ^[2].

Employers also report they have not yet seen a clear return on investment. In the Business Group on Health data, while more than half of employers covering GLP-1s for weight management expect significant clinical benefits, few have yet seen evidence — such as reduced obesity rates or fewer employees needing bariatric surgery — in their aggregated claims ^[5]. Whether GLP-1 spending pays for itself through reduced medical costs elsewhere remains contested and is not settled by these surveys.

Industry observers describe a squeeze between falling unit prices and growing volume. “Even though we have seen the unit cost come down, the patient population keeps growing,” said Louis Zollo, a pharmacy practice leader at the consultancy Segal ^[4]. Dan Mendelson, CEO of Morgan Health, a healthcare unit owned by JPMorgan, said the pills are set to push the cost of individual treatments down this year, “but every year there’s going to be market growth… so on aggregate this still represents a major cost driver for employers” ^[4].

Will the cheaper GLP-1 pills make employer coverage more or less likely?

Probably less likely, at least in the near term. Novo Nordisk launched the Wegovy pill in January and Eli Lilly began selling Foundayo in April, with both starting at about $149 per month ^[4]. The oral version of Wegovy was approved by the FDA late in 2025, and Foundayo was approved in April 2026 ^[5]. That roughly $149 starting price is a discounted cash price on the drugmakers’ own websites, tied to a deal with the Trump administration and its site TrumpRx.gov — it is not what employer plans pay ^[4].

And those discounted cash prices have not translated into lower employer costs so far. In the Business Group on Health survey, 87% of employers expect the new oral GLP-1s to result in higher demand overall, and only 9% expect a decrease in price ^{[3] [5]}. Demand has increased this year because the oral options are attracting people who have never before tried GLP-1s, which has kept employer costs high, according to five industry experts ^[4].

The pills also appear somewhat less effective on weight: Foundayo and oral Wegovy have been shown to reduce weight by 11% and 14% respectively, less than the injected drugs, though preferable for patients who fear needles ^[4]. Nick Conway, president of Rx solutions at the benefits firm NFP, said a once-daily pill will likely expand the population of people who are both eligible and willing to pursue treatment beyond today’s injectable users ^[5]. Aon has observed injectable customers shifting to oral versions as well as new GLP-1 patients choosing the pills ^[4].

What rules do employers attach to coverage instead of dropping it?

Most employers that keep weight-loss coverage are managing it more tightly rather than dropping it outright. In the Business Group on Health survey, 69% of employers validate eligibility through biometrics and 45% require participation in a weight management program ^[2]. KFF found that 34% of firms covering GLP-1s for weight loss require enrollees to meet with a dietitian, case manager or therapist, or participate in a lifestyle program, before the medications are covered — up from 10% of firms in 2024 ^{[7] [6]}.

Other common tools include:

• Limiting prescribing to designated providers, specialists or preferred clinical programs ^{[2] [5]}
• Covering GLP-1s only for diabetes, or narrowing weight-loss eligibility to people with higher cardiometabolic risk and requiring added clinical documentation ^[2]
• Prior authorization, step therapy, trying lower-cost alternatives first, and formulary exclusions ^{[6] [5] [7]}
• Exploring alternative procurement, direct-to-employer and direct-to-consumer or self-pay pathways ^{[2] [5]}

Employer focus groups convened by KFF described similar approaches: requiring coaching with periodic reevaluation, and grandfathering current users while requiring new participants to join a program ^[7].

What do cash-pay prices look like if your plan drops coverage?

Employers dropping coverage are nudging patients toward direct-to-consumer prescription programs, and major retailers are racing to fill the void ^[8]. These are posted program prices with conditions — not guaranteed all-in monthly costs.

Program	Posted price	Conditions
LillyDirect [8]	$299 to $449 a month	Better pricing tied to refilling within 45 days
NovoCare [8]	$199 for introductory months, later stepping up to $349	Price rises after the introductory period
Costco–Sesame [8]	Wegovy around $349	Requires a Costco membership ($65 card)
Oral GLP-1s (Wegovy pill, Foundayo) [4]	About $149 per month to start	Drugmaker website pricing tied to a Trump administration deal and TrumpRx.gov

Some direct-to-consumer programs start as low as $25 a month ^[8]. Walmart is a retail pickup point for LillyDirect and is the nation’s fifth-largest prescription provider with nearly 4,600 pharmacies ^[8].

Employers are watching these prices closely. Lauren Remspecher, a director at the Purchaser Business Group on Health, said many employers are concerned they are not seeing the same savings in their deals with pharmacy benefit managers as customers who purchase directly and pay cash — though the transparency of direct-to-consumer and government-negotiated pricing now lets employers see how much more they are paying and where there is room for improvement ^[4].

Can an employer legally refuse to cover weight-loss drugs?

Generally, yes. No federal law requires employer plans to cover GLP-1s for weight loss or for diabetes, and the Affordable Care Act’s preventive-care mandates do not cover these drugs ^[6]. Employers that sponsor fully insured plans must choose from plan options that comply with state insurance mandates, while self-funded plans generally are not bound by those state mandates ^[6].

State mandates are rare. North Dakota is currently the only state that requires GLP-1 and GIP coverage in private, fully insured plans: beginning in 2025, its essential health benefit benchmark requires prescription drug coverage of GLP-1s and GIPs for diabetes prevention and treatment of insulin resistance, metabolic syndrome or morbid obesity — but this applies only to individual and small-group ACA plans, not grandfathered or large-group plans ^[6]. New Hampshire lawmakers introduced a bill, SB455-FN, that would require certain fully insured commercial plans to cover GLP-1s under certain circumstances; similar bills in California (AB 575) and Maine failed last year ^[6].

Disability law is mixed and fact-dependent. No federal law explicitly bars weight-based discrimination, and most federal appeals courts have held that obesity — unless caused by an underlying health condition — is not a protected disability under the ADA ^[6]. But district courts have produced mixed decisions on that issue, the EEOC has filed disability-related lawsuits on behalf of morbidly obese employees, and some state and local antidiscrimination laws include weight as a protected class ^[6]. Several employees have sued health insurance companies for excluding coverage of GLP-1s prescribed solely to treat obesity, arguing the exclusion constitutes disability discrimination under the ACA; those suits have so far targeted insurers or third parties ^[6].

Indication-based coverage — covering GLP-1s for diabetes but not for obesity — can potentially raise concerns under the ADA, the ACA, HIPAA’s nondiscrimination requirements, or the Mental Health Parity and Addiction Equity Act ^[6]. This is an evolving area of law, and no court outcome is guaranteed either way.

Does the diagnosis matter for coverage?

Yes, because the FDA has approved only some of these drugs for weight-related uses. With diet and exercise, the FDA has approved Wegovy and Zepbound to reduce excess body weight and maintain weight reduction long term in adults with obesity, or adults who are overweight with at least one weight-related condition ^[6]. Wegovy is also approved to reduce the risk of cardiovascular death, heart attack and stroke in adults with cardiovascular disease and either obesity or overweight, and Zepbound is approved to treat moderate to severe obstructive sleep apnea in adults with obesity ^[6].

Ozempic and Mounjaro are not FDA-approved for weight loss or weight management, though clinicians sometimes prescribe them off-label for those uses ^[6]. Semaglutides include Ozempic and Wegovy; tirzepatides — Mounjaro and Zepbound — are technically classified differently because they act on both GLP-1 and GIP ^[6].

This matters practically: a plan may end coverage for weight management while continuing it for diabetes or another approved indication, so the diagnosis on the prescription can change the answer ^{[2] [7]}.

Has any insurer cut GLP-1 coverage for its own employees?

Yes. Health insurer Cigna ceased coverage of weight-loss GLP-1s for its own employees effective July, telling staff they could buy the medicines elsewhere, as Reuters first reported ^[4].

What can you do if your plan drops or restricts coverage?

Start with the plan documents. Coverage may end for weight management while continuing for diabetes or other indications, so read the exact wording before assuming the drug is no longer covered at all ^{[2] [7]}. Questions about what a specific plan covers, who is eligible and how prior authorization works should go to the plan administrator ^[2].

If a request is denied, appeal paths exist. In KFF’s employer focus groups, one employer described a plan where requests were usually denied the first time and employees had to go through an appeal process ^[7].

If obesity coverage ends, employers often point to other weight-management options they do cover, such as other anti-obesity medications, lifestyle and nutrition programs, or bariatric centers of excellence ^[2]. Employers are advised to communicate clearly what is covered, who is eligible and how prior authorization works ^[2].

Cash-pay programs are the fallback if coverage ends, with posted prices including the roughly $149 per month starting price for the pills, LillyDirect’s $299 to $449, and NovoCare’s $199 introductory price stepping up to $349 ^{[4] [8]}. Treatment expectations also matter: employers frame successful treatment as requiring sustained engagement with healthcare providers, lifestyle modifications and continued monitoring ^[2]. Decisions about starting, switching or stopping a medication belong with a prescriber.

Where is employer GLP-1 coverage heading?

GLP-1 costs have moved the conversation beyond HR and benefits teams to the C-suite, with Business Group on Health survey findings showing 88% of senior leaders paying greater attention to health and well-being initiatives and healthcare costs ^[2]. Ellen Kelsay, the group’s president and CEO, said that against the backdrop of anticipated double-digit healthcare cost increases, “fueled to a large degree by GLP-1s and overall prescription drug costs, companies cannot ignore the reality that GLP-1s have significant implications for healthcare budgets — and overall affordability” ^{[3] [5]}.

Sara Izadi, chief clinical officer at the health technology company Judi Health, expects more direct-to-employer and self-pay funding models, and says the biggest wildcard is that as manufacturers lower net prices and GLP-1 competition increases, coverage can stabilize and even expand — with employers moving toward a far more managed, outcomes-focused approach rather than blanket coverage or blanket exclusion ^[5].

Meanwhile, retailers including Walmart, Costco, CVS and Amazon are competing to become the front door for obesity care as coverage shifts toward cash purchasing ^[8].

Sources

1. KFF. 2025 Employer Health Benefits Survey. October 22, 2025.
2. Business Group on Health. How Are Employers Managing GLP-1 Coverage Amid Rising Demand and Costs?
3. Fierce Healthcare. Nearly 8 in 10 employers say GLP-1 coverage drives up benefit costs: Business Group on Health. May 6, 2026.
4. Reuters. Some US employers to drop coverage of GLP-1 obesity drugs in 2027 as use increases. June 11, 2026.
5. SHRM. 1 in 10 Employers Likely Will Stop GLP-1 Coverage in 2027.
6. Fisher Phillips LLP. Employer FAQs on the Rise of GLP-1 Drugs for Weight Loss and the Workplace Impact. February 19, 2026.
7. Peterson-KFF Health System Tracker. Perspectives from employers on the costs and issues associated with covering GLP-1 agonists for weight loss. October 22, 2025.
8. CNBC. As Americans go direct with GLP-1 prescriptions, Walmart, Costco, Amazon will be big weight-loss winners. August 1, 2026.
9. Simplefill. Employers Are Dropping GLP-1 Coverage.
10. Mercer. Trump announces lower GLP-1 prices. Will employer plans see them too?
11. Health Exec. Employer healthcare expenses could spike 9.5% in 2027, pressured by GLP-1s. August 20, 2026.
12. National Bureau of Economic Research. Do GLP-1 Medications Pay for Themselves? Working Paper 34678. January 2026, revised July 2026.
13. IQVIA. The outlook for obesity from 2026 to 2030. April 21, 2026.
14. Reuters. Cigna drops coverage of GLP-1 obesity drugs for its own employees. June 2, 2026.
15. Eli Lilly and Company. Lilly Employer Connect platform launches with over fifteen independent program administrators offering tailored obesity coverage options to expand access to patients. March 5, 2026.
16. HR Brew. What HR should know about Eli Lilly’s direct-to-employer offering. March 12, 2026.
17. Omada Health. Omada Health Joins Lilly Employer Connect, Expanding Its Access Pathways for GLP-1 Care as Patients Seek More Lifestyle Support. May 7, 2026.
18. GoodRx. GoodRx to Expand Employer-Sponsored Access to Zepbound KwikPen. March 6, 2026.
19. CVS Health. CVS Caremark delivers affordability and access to GLP-1 weight management medications with expanded coverage options. May 28, 2026.
20. Healthcare Dive. CVS obesity drug deal puts Lilly on equal footing with Novo.
21. Yahoo Finance. CVS Caremark adds Zepbound and Foundayo to insurance coverage.
22. Fierce Pharma. CVS restores coverage of Eli Lilly obesity med Zepbound, adds new pill Foundayo. May 28, 2026.
23. Novo Nordisk. Financial report for the period 1 January 2026 to 30 June 2026. August 4, 2026.
24. National Council on Aging. Medicare GLP-1 Bridge Program: Eligibility, Costs, and Coverage.
25. Thomson Reuters. First Circuit Rejects ACA Section 1557 Challenge to Plan’s Weight-Loss Drug Exclusion. April 1, 2026.
26. HR Dive. Worker did not plausibly argue obesity was a disability, 1st Circuit finds.
27. Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes, Obesity & Metabolism. August 2022.
28. JAMA. Journal article.
29. The Washington Post. Why it may become harder to get coverage for GLP-1 weight-loss drugs. September 15, 2026.
30. Axios. Large employers drop health benefits as costs rise. September 4, 2026.